Baxter International Faces Class Action for Alleged Defects in Novum Large Volume Pump
- Baxter International faces a class action lawsuit over alleged defects in the Novum Large Volume Pump endangering patient safety.
- The lawsuit claims Baxter issued misleading statements and failed to address malfunctions despite awareness of associated injuries and fatalities.
- Investors have until December 15, 2025, to apply for lead plaintiff status in the ongoing securities fraud case against Baxter.
Baxter International Faces Class Action Over Alleged Product Defects
Baxter International, Inc. is currently embroiled in a class action lawsuit that raises serious concerns about the safety and efficacy of its medical device, the Novum Large Volume Pump (LVP). This lawsuit, initiated by the law firm Levi & Korsinsky, LLP, alleges that Baxter knowingly issued misleading statements regarding the device’s performance between February 23, 2022, and July 30, 2025. According to the complaint, the Novum LVP suffers from systemic defects that lead to malfunctions such as underinfusion, overinfusion, and a complete failure to deliver fluids. These defects not only jeopardize patient safety but also compromise the integrity of Baxter's reputation in the healthcare sector.
The lawsuit further contends that Baxter failed to adequately address the malfunctions associated with the Novum LVP despite being aware of multiple incidents, including injuries and fatalities linked to the device. Instead of taking substantial remedial actions, Baxter allegedly issued insufficient customer alerts, which did not fully disclose the risks involved. This lack of transparency has resulted in an increased likelihood that healthcare providers would be advised to withdraw existing Novum LVPs from use, leading to a potential halt in new sales. The implications of these allegations are significant, as they challenge not only the operational integrity of Baxter's medical devices but also the trust that healthcare providers and patients place in the company's products.
As the lawsuit unfolds, affected investors have until December 15, 2025, to apply for lead plaintiff status. The claims of securities fraud highlight a critical intersection of patient safety and corporate accountability within the medical device industry. With Baxter’s public statements deemed materially false and misleading, the outcome of the lawsuit could have far-reaching consequences on the company's future operations and its standing in the competitive healthcare market. Investors participating in the class action are assured that they will not incur upfront costs and may be entitled to compensation for their losses.
In parallel to the actions taken by Levi & Korsinsky, the Law Offices of Frank R. Cruz have also announced opportunities for affected investors to lead a separate securities fraud class action lawsuit against Baxter. Both firms emphasize the importance of investor participation, highlighting the potential for significant recoveries based on the outcomes of these legal proceedings. As the situation develops, stakeholders in Baxter International will closely monitor the implications of these legal challenges on the company’s operational practices and product safety measures.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

